About genelux corp - GNLX
Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay on September 4, 2001 and is headquartered in Westlake Village, CA.
GNLX At a Glance
Genelux Corp.
2625 Townsgate Road
Westlake Village, California 91361
| Phone | 1-805-267-9889 | Revenue | 8.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -32,145,000.00 | |
| Sector | Health Technology | Employees | 26 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GNLX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 20,261.207 |
| Price to Book Ratio | 14.241 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.57 |
| Enterprise Value to Sales | 18,647.457 |
| Total Debt to Enterprise Value | 0.011 |
GNLX Efficiency
| Revenue/Employee | 307.692 |
| Income Per Employee | -1,236,346.154 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.00 |
GNLX Liquidity
| Current Ratio | 2.431 |
| Quick Ratio | 2.431 |
| Cash Ratio | 2.345 |
GNLX Profitability
| Gross Margin | -7,075.00 |
| Operating Margin | -415,175.00 |
| Pretax Margin | -401,812.50 |
| Net Margin | -401,812.50 |
| Return on Assets | -119.625 |
| Return on Equity | -169.998 |
| Return on Total Capital | -242.989 |
| Return on Invested Capital | -158.291 |
GNLX Capital Structure
| Total Debt to Total Equity | 14.596 |
| Total Debt to Total Capital | 12.737 |
| Total Debt to Total Assets | 8.856 |
| Long-Term Debt to Equity | 10.897 |
| Long-Term Debt to Total Capital | 9.509 |